pharmafile.com
Open in
urlscan Pro
199.16.172.219
Public Scan
Submitted URL: http://pharmafile.com/
Effective URL: https://pharmafile.com/
Submission Tags: tranco_l324
Submission: On March 15 via api from DE — Scanned from DE
Effective URL: https://pharmafile.com/
Submission Tags: tranco_l324
Submission: On March 15 via api from DE — Scanned from DE
Form analysis 3 forms found in the DOM
#
<form role="search" action="#" autocomplete="off" aria-label="Search form"><input type="search" class="orig" placeholder="Search here..." name="phrase" value="" aria-label="Search input" autocomplete="off"><input type="text" class="autocomplete"
name="phrase" value="" aria-label="Search autocomplete input" aria-hidden="true" tabindex="-1" autocomplete="off" disabled=""></form>Name: options —
<form name="options" class="asp-fss-flex" aria-label="Search settings form" autocomplete="off"><input type="hidden" name="current_page_id" value="-1"><input type="hidden" name="qtranslate_lang" value="0"><input type="hidden" name="filters_changed"
value="0"><input type="hidden" name="filters_initial" value="1">
<div style="clear:both;"></div>
</form>Name: wpv-filter-39484 — GET /?wpv_view_count=39484
<form autocomplete="off" name="wpv-filter-39484" action="/?wpv_view_count=39484" method="get" class="wpv-filter-form js-wpv-filter-form js-wpv-filter-form-39484 js-wpv-form-full" data-viewnumber="39484" data-viewid="39484"
data-viewhash="eyJuYW1lIjoiaG9tZXBhZ2UtYWxsLWFydGljbGVzLXYyIn0=" data-viewwidgetid="0" data-orderby="" data-order="" data-orderbyas="" data-orderbysecond="" data-ordersecond=""
data-parametric="{"query":"normal","id":"39484","view_id":"39484","widget_id":0,"view_hash":"39484","action":"\/?wpv_view_count=39484","sort":{"orderby":"","order":"","orderby_as":"","orderby_second":"","order_second":""},"orderby":"","order":"","orderby_as":"","orderby_second":"","order_second":"","ajax_form":"","ajax_results":"","effect":"fade","prebefore":"","before":"","after":"","attributes":[],"environment":{"current_post_id":0,"parent_post_id":0,"parent_term_id":0,"parent_user_id":0,"archive":{"type":"native","name":"home","data":[]}},"loop":{"type":"","name":"","data":[],"id":0}}"
data-attributes="[]"
data-environment="{"current_post_id":0,"parent_post_id":0,"parent_term_id":0,"parent_user_id":0,"archive":{"type":"native","name":"home","data":[]}}">
<input type="hidden" class="js-wpv-dps-filter-data js-wpv-filter-data-for-this-form" data-action="/?wpv_view_count=39484" data-page="1" data-ajax="disable" data-effect="fade" data-maxpages="1098" data-ajaxprebefore="" data-ajaxbefore=""
data-ajaxafter=""><input class="wpv_view_count wpv_view_count-39484" type="hidden" name="wpv_view_count" value="39484">
</form>Text Content
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store
and/or access device information. Consenting to these technologies will allow us
to process data such as browsing behavior or unique IDs on this site. Not
consenting or withdrawing consent, may adversely affect certain features and
functions.
Functional Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose
of enabling the use of a specific service explicitly requested by the subscriber
or user, or for the sole purpose of carrying out the transmission of a
communication over an electronic communications network.
Preferences Preferences
The technical storage or access is necessary for the legitimate purpose of
storing preferences that are not requested by the subscriber or user.
Anonymised Statistics Anonymised Statistics
The technical storage or access that is used exclusively for statistical
purposes. The technical storage or access that is used exclusively for anonymous
statistical purposes. Without a subpoena, voluntary compliance on the part of
your Internet Service Provider, or additional records from a third party,
information stored or retrieved for this purpose alone cannot usually be used to
identify you.
Marketing Marketing
The technical storage or access is required to create user profiles to send
advertising, or to track the user on a website or across several websites for
similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about
these purposes
Accept Deny View preferences Save preferences View preferences
Privacy Policy {title}
* About us
* Advertise
* Contact
* About us
* Advertise
* Contact
* Follow
* Follow
* Follow
* home
* News
* News
* Press releases
* Features
* Features
* Thought Leadership
* White papers
* Case studies
* Appointments
* Business Sectors
* Business Services
* Manufacturing and Production
* Medical Communications
* Research and Development
* Sales and Marketing
* Webinars
* Jobs
* Pharmafocus
* Pharmafocus Issues
* Pharmafocus Articles
* Pharmafile
* Pharmafile Issues
* Pharmafile Articles
* Subscribe
* search
* home
* News
* News
* Press releases
* Features
* Features
* Thought Leadership
* White papers
* Case studies
* Appointments
* Business Sectors
* Business Services
* Manufacturing and Production
* Medical Communications
* Research and Development
* Sales and Marketing
* Webinars
* Jobs
* Pharmafocus
* Pharmafocus Issues
* Pharmafocus Articles
* Pharmafile
* Pharmafile Issues
* Pharmafile Articles
* Subscribe
* search
Search
Advanced Search
ASTRAZENECA TO ACQUIRE AMOLYT PHARMA FOR UP TO $1.05BN
March 14, 2024
Business Services Amolyt Pharma, AstraZeneca, Rare Diseases, acquisition, rare
diseases
AstraZeneca has announced that it has entered into a definitive agreement under
which it will acquire Amolyt Pharma for up …
News
BAYER AND AIGNOSTICS TO COLLABORATE FOR AI ONCOLOGY RESEARCH
March 14, 2024
Research and Development AI, Bayer, Oncology, research
Bayer and Aignostics have announced that they have entered into a strategic
collaboration for several artificial intelligence (AI)-powered approaches for …
News
EC APPROVES PFIZER’S PREVENAR 20 TO PROTECT PAEDIATRIC PATIENTS AGAINST
PNEUMOCOCCAL DISEASE
March 13, 2024
Research and Development EC, EMA, Infections and infestations, Prevnar 20,
pneumococcal disease
Pfizer has announced that the European Commission (EC) has granted marketing
authorisation for Prevenar 20, the company’s 20-valent pneumococcal conjugate …
News
MERCK PLANS TO CONDUCT TRIALS FOR HPV VACCINES
March 13, 2024
Research and Development Immunology, Merck, vaccines
Merck, known as MSD outside of the US and Canada, has announced that it is
planning to initiate clinical development …
News
SANOFI SHARES PHASE 2B RESULTS FOR DERMATITIS TREATMENT
March 12, 2024
Research and Development Dermatology, Sanofi, amlitelimab, atopic dermatitis,
clinical trial, dermatitis
Sanofi has shared positive results from part 2 of the investigational phase 2b
STREAM-AD study of amlitelimab for adult patients …
News
MERCK COMPLETES ACQUISITION OF HARPOON THERAPEUTICS FOR $650M
March 12, 2024
Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer
Merck, known as MSD outside of the US and Canada, has announced that it has
completed the acquisition of Harpoon …
News
JOHNSON & JOHNSON ACQUIRES AMBRX BIOPHARMA FOR APPROXIMATELY $2BN
March 11, 2024
Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology,
acquisition
Johnson & Johnson (J&J) has announced that it has successfully completed its
acquisition of Ambrx Biopharma in an all-cash merger …
News
ASPIRE PHARMA ACQUIRES CENOTÉ PHARMA
March 11, 2024
Business Services Aspire Pharma, Cenoté Pharma, Pharmacy, acquisition
Aspire Pharma has announced that it has successfully acquired Cenoté Pharma as
part of its plan to supplement its growth …
News
BEIGENE’S BRUKINSA GAINS FDA ACCELERATED APPROVAL FOR FOLLICULAR LYMPHOMA
TREATMENT
March 8, 2024
Medical Communications BeiGene, Brukinsa, FDA, Oncology, follicular lymphoma
BeiGene has announced that the US Food and Drug Administration (FDA) has granted
accelerated approval to Brukinsa (zanubrutinib) for the …
News
ROCHE SHARES DATA ON NOVEL SOLUTION FOR CONTINUOUS GLUCOSE MONITORING
March 8, 2024
Research and Development Diabetes, Medical device, Roche, continuous glucose
monitoring, diabetes
Roche has shared the latest data on its novel solution for continuous glucose
monitoring (CGM), including a CGM sensor and …
News
GSK SHARES RESULTS FROM PHASE 3 TRIAL FOR BLENREP FOR TREATMENT OF MULTIPLE
MYELOMA
March 7, 2024
Research and Development Blenrep, GSK, Oncology, clinical trial, multiple
myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8
phase 3 head-to-head trial which assesses Blenrep (belantamab …
News
GILEAD AND MERCK SHARE DATA FROM PHASE 2 TRIAL OF HIV TREATMENT
March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have
announced results from the phase 2 …
News
MEASLES: THE UK’S NEXT EPIDEMIC?
March 6, 2024
MMR, measles, vaccines
Recently, the UK has seen a rapid increase in the number of cases of measles,
along with a drop in …
Feature
FDA APPROVES SANDOZ’S DENOSUMAB BIOSIMILARS
March 6, 2024
Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost,
denosumab
Sandoz has announced that the US Food and Drug Administration (FDA) has approved
Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …
News
REGENXBIO ANNOUNCES INITIAL EFFICACY DATA FROM PHASE 1/2 AFFINITY DUCHENNE TRIAL
March 6, 2024
Research and Development Duchenne Muscular Dystrophy, Musculo-skeletal disorder,
Regenxbio, clinical trial
Regenxbio has announced additional interim safety data from its phase 1/2
AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne …
News
GSK’S JEMPERLI RECOMMENDED BY NICE FOR ENDOMETRIAL CANCER TREATMENT
March 5, 2024
Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence
(NICE) has recommended the use of Jemperli (dostarlimab) …
News
NOVARTIS SHARES NEW DATA FOR ZOLGENSMA IN CHILDREN WITH SMA
March 5, 2024
Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy
Novartis has announced new data to continue the support of the clinical benefits
of Zolgensma (onasmenogene abeparvovec), for the treatment …
News
FDA APPROVES J&J’S RYBREVANT WITH CHEMOTHERAPY FOR NSCLC TREATMENT
March 4, 2024
Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant
Johnson & Johnson have announced that the US Food and Drug Administration (FDA)
has approved Rybrevant (amibantamab-vmjw) following a priority …
News
EMA VALIDATES TWO APPLICATIONS FOR DATOPOTAMAB DERUXTECAN FOR CANCER TREATMENTS
March 4, 2024
Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab
deruxtecan
AstraZeneca has announced that the European Medicines Agency (EMA) has validated
to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …
News
CARDIFF ONCOLOGY DOSES FIRST PATIENT IN COLORECTAL CANCER TRIAL
March 1, 2024
Research and Development Cardiff Oncology, Oncology, clinical trial, colorectal
cancer
Cardiff Oncology has announced that it has dosed the first patient in its
randomised first-line phase 2 trial, CRDF-004, for …
News
VIRACTA THERAPEUTICS COMPLETES ENROLMENT FOR T-CELL LYMPHOMA COHORT IN NAVAL-1
TRIAL
March 1, 2024
Medical Communications Oncology, Viracta Therapeutics, lymphoma
Viracta Therapeutics has announced that it has completed stage 2 enrolment into
the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …
News
* 1
* 2
* 3
* 4
* 5
* ...
* 1098
* Next
* Last
News Alerts and Subscriptions
LATEST CONTENT
AstraZeneca to acquire Amolyt Pharma for up to $1.05bn
March 14, 2024
--------------------------------------------------------------------------------
Bayer and Aignostics to collaborate for AI oncology research
March 14, 2024
--------------------------------------------------------------------------------
EC approves Pfizer’s Prevenar 20 to protect paediatric patients against
pneumococcal disease
March 13, 2024
--------------------------------------------------------------------------------
Merck plans to conduct trials for HPV vaccines
March 13, 2024
--------------------------------------------------------------------------------
Sanofi shares phase 2b results for dermatitis treatment
March 12, 2024
--------------------------------------------------------------------------------
Join our Twitter / X group here
* Privacy Policy
* Terms of Service
* Cookie Policy
* About us
* Media Information
* Newsletters
* RSS
* Subscribe
* PMGroup Worldwide Ltd
* Privacy Policy
* Terms of Service
* Cookie Policy
* About us
* Media Information
* Newsletters
* RSS
* Subscribe
* PMGroup Worldwide Ltd
All content copyright © Samedan Ltd 2024
Manage consent